Daily briefings
Editor’s Briefing: November 18, 2026
In Short. SELLAS said a leukemia vaccine prolonged survival in a Phase 3 trial. The FDA approved GSK's Nelkarmi for lung cancer and Beren's Lembaz for a rare disease. Merck stopped a blood-cancer program after a late-stage review.
SELLAS reports that galinpepimut-S prolonged survival in a Phase 3 leukemia trial
ACUTE MYELOID leukemia is a blood cancer in which abnormal white cells grow quickly in the bone marrow. On Tuesday SELLAS Life Sciences reported results from REGAL, a Phase 3 trial of galinpepimut-S as maintenance treatment after a second remission (announcement). The people in the trial were not eligible for, or could not have, a donor stem-cell transplant. Galinpepimut-S is an experimental vaccine designed to train the immune system to attack leftover leukemia cells that display a protein called WT1.
The trial assigned 126 people at random, in equal groups, to the vaccine alone or to a doctor's choice of best available treatment, which could include observation or other medicines. The main goal was how long people lived. The analysis was run after a pre-set 80 deaths. The vaccine reduced the risk of death by 41% versus the comparator (hazard ratio 0.59, p=0.035). The median time people lived was 24.0 months on the vaccine and 14.7 months on the comparator. The company did not report a confidence interval for the hazard ratio. Unwanted effects related to treatment were mostly mild or moderate, most often redness or swelling at the injection site.
The FDA grants accelerated approval to GSK's Nelkarmi in a form of lung cancer
NON-SMALL CELL lung cancer is the most common form of lung cancer. Some of those tumors are driven by a change in a gene called ALK and are first treated with medicines that block that signal, known as tyrosine kinase inhibitors. On Tuesday the FDA granted accelerated approval, an approval based on tumor shrinkage that may depend on later trials to confirm a benefit, to GSK's Nelkarmi (neladalkib) (announcement). The approval is for adults with locally advanced or metastatic ALK-positive disease after alectinib alone, or after two or more such blockers plus platinum chemotherapy. Nelkarmi is a daily pill that blocks ALK.
The approval rests on ALKOVE-1, a Phase 1/2 trial. Among 67 people whose only prior ALK blocker was alectinib, 33 (49%) had a confirmed response, and 76% of those who responded still had a response at six months. Among 155 people who had received two or more ALK blockers and chemotherapy, 50 (32%) had a confirmed response. Of those who responded, 69% still had a response at six months. The most common unwanted effects included liver injury, muscle and joint pain, constipation, taste change, nerve symptoms, swelling, and tiredness.
The FDA approves Beren's Lembaz to reduce the risk of death in infantile-onset Niemann-Pick disease type C
NIEMANN-PICK disease type C is a rare inherited illness in which cells cannot move cholesterol to the places that need it, so fats build up, especially in the brain. On Tuesday the FDA approved Beren Therapeutics' Lembaz (adrabetadex) (announcement). The approval is to reduce the risk of death in adults and children who weigh at least 7 kilograms and whose neurological symptoms began before age 6. A clinician injects the medicine into the spinal canal every two weeks.
The FDA based the approval on survival in 36 people treated with Lembaz across three clinical studies and an expanded-access program, compared with matched external controls. People on the medicine had a 55% reduction in the risk of death. The median time people lived was 8.5 years in the treated group and 4.9 years in the control group. The label carries a boxed warning that the medicine can cause hearing damage, including permanent hearing loss, and requires hearing tests before and during treatment.
Merck stops the nemtabrutinib program after a Phase 3 review
CHRONIC LYMPHOCYTIC leukemia and small lymphocytic lymphoma are closely related cancers of white blood cells. On Tuesday afternoon Merck said it would stop clinical development of nemtabrutinib (announcement). Nemtabrutinib is an experimental oral medicine designed to block Bruton's tyrosine kinase, a signaling protein used by some blood-cancer cells. An external data-monitoring committee reviewing the Phase 3 BELLWAVE-011 trial suggested that the benefits may not outweigh the risks in that study. Merck said it then reviewed the data in full and decided to stop the wider BELLWAVE program, including two other Phase 3 trials, BELLWAVE-008 and BELLWAVE-010. The company did not publish the trial results. It said analyses are continuing and that the findings will be shared with the scientific community.
What to watch
By November 22 the FDA is due to decide on Capricor's deramiocel for Duchenne muscular dystrophy, and on Savara's inhaled molgramostim for autoimmune pulmonary alveolar proteinosis, a rare disease in which a protein-rich fluid builds up in the lungs. A decision on BridgeBio's BBP-418 for limb-girdle muscular dystrophy type 2I/R9, an inherited muscle-wasting disease, is due on November 27.
Sources
- SELLAS: positive pivotal Phase 3 REGAL data for galinpepimut-S in AML
- GSK: Nelkarmi (neladalkib) approved in the US for previously treated ALK-positiv
- FDA: accelerated approval of neladalkib
- Beren Therapeutics: US FDA approval of Lembaz
- FDA: first drug shown to help infantile-onset Niemann-Pick disease type C patien
- Merck: update on BELLWAVE program evaluating nemtabrutinib